Dersimelagon clinical trials
Also written MT-7117.
Its developmentBy Tanabe Pharma, step by step13 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses dersimelagon is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 13 · Other 0
Mitsubishi Tanabe Pharma America Inc. (6) · Tanabe Pharma America, Inc. (5) · Tanabe Pharma Corporation (1) · Mitsubishi Tanabe Pharma Corporation (1)
Studies
Open first, then newest update. How each study uses dersimelagon is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)Active, not recruitingPhase 3Tanabe Pharma America, Inc.NCT05005975Written as MT-7117How we know
- INcreased Sun Exposure Without Pain In Research Participants With EPP or XLPCompletedPhase 3Tanabe Pharma America, Inc.NCT06144840Written as DersimelagonHow we know
- The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.CompletedPhase 1Tanabe Pharma CorporationNCT06994286Written as MT-7117How we know
- Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic ProtoporphyriaCompletedPhase 2Tanabe Pharma America, Inc.NCT03520036Written as MT-7117 low doseHow we know
- Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic SclerosisCompletedPhase 2Tanabe Pharma America, Inc.NCT04440592Written as MT-7117How we know
- Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked ProtoporphyriaCompletedPhase 3Tanabe Pharma America, Inc.NCT04402489Written as MT-7117 Low DoseHow we know
- Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic FunctionCompletedPhase 1Mitsubishi Tanabe Pharma America Inc.NCT04116476Written as MT-7117How we know
- Mass Balance Study With MT-7117CompletedPhase 1Mitsubishi Tanabe Pharma America Inc.NCT03503266Written as [14C] MT-7117How we know
- Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy SubjectsCompletedPhase 1Mitsubishi Tanabe Pharma America Inc.NCT05241535Written as MT-7117How we know
- Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump InhibitorCompletedPhase 1Mitsubishi Tanabe Pharma America Inc.NCT03688022Written as MT-7117How we know
- PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal FunctionCompletedPhase 1Mitsubishi Tanabe Pharma America Inc.NCT04656795Written as MT-7117How we know
- Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy SubjectsCompletedPhase 1Mitsubishi Tanabe Pharma America Inc.NCT04793295Written as MT-7117How we know
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy SubjectsCompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT02834442Written as MT-7117How we know
Codes
What other systems call dersimelagon · ClinicalTrials.gg INT014306
- UNII (FDA) 1CWH5SV4G2DERSIMELAGONOne source FDA
- NCI Thesaurus C166490DersimelagonOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1CWH5SV4G2 | DERSIMELAGON | One source FDA |
| NCI Thesaurus | C166490 | Dersimelagon | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.